Mereo BioPharma Group paid its 3 named executives $5.0M in total in FY2025 (Dec). CEO Dr. Denise Scots-Knight was paid $2.7M of that.
Pay$100 in the stock at the end of FY22 → $56
Pay of each named executive
Dr. Denise Scots-KnightChief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Charles SermonGeneral Counsel
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
Christine FoxChief Financial Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.